TQ Therapeutics Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Series A
- (Upcoming)
- Investors
-
4
TQ Therapeutics General Information
Description
Developer of a modular cell-targeted modification platform designed to enable in-vivo generation of autologous cell and gene therapy products. The company offers an extracorporeal in-vivo mRNA-T-cell engineering approach based on a proprietary modular architecture, enabling healthcare providers to create personalized therapeutics across multiple disease areas with improved safety and adaptability.
Contact Information
Website
www.tqtherapeutics.comCorporate Office
- Fraunhoferstr. 1
- 82152 Planegg
- Germany
Corporate Office
- Fraunhoferstr. 1
- 82152 Planegg
- Germany
TQ Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | Upcoming | Startup | ||||
| 1. Seed Round | 15-Jan-2024 | Completed | Startup |
TQ Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
TQ Therapeutics Patents
TQ Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026224219-A1 | A method of manufacturing a cellular therapy product and respective kits and devices | Pending | 22-Apr-2025 | ||
| EP-4725578-A1 | Column designs for affinity chromatography | Pending | 08-Oct-2024 | ||
| US-20260098840-A1 | Column designs for affinity chromatography | Pending | 08-Oct-2024 | ||
| AU-2024364039-A1 | A method of manufacturing a cellular therapy product and respective kits and devices | Pending | 18-Oct-2023 | ||
| EP-4795152-A1 | A method of manufacturing a cellular therapy product and respective kits and devices | Pending | 18-Oct-2023 | C12N5/0636 |
TQ Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
TQ Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bristol-Myers Squibb | Corporation | Minority | ||
| High-Tech Gründerfonds | Venture Capital | Minority | ||
| Juno Therapeutics | Corporation | Minority | ||
| Ventura BioMed Investors | Venture Capital | Minority |
TQ Therapeutics Acquisitions (1)
TQ Therapeutics’s most recent deal was a Merger/Acquisition with Juno Therapeutics (Munich, Germany). The deal was made on 28-May-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Juno Therapeutics (Munich, Germany) | 28-May-2025 | Merger/Acquisition | Drug Discovery |
TQ Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Stage Cell Therapeutics | Gottingen, Germany | 2005 |
TQ Therapeutics FAQs
-
When was TQ Therapeutics founded?
TQ Therapeutics was founded in 2023.
-
Where is TQ Therapeutics headquartered?
TQ Therapeutics is headquartered in Planegg, Germany.
-
What is the size of TQ Therapeutics?
TQ Therapeutics has 15 total employees.
-
What industry is TQ Therapeutics in?
TQ Therapeutics’s primary industry is Pharmaceuticals.
-
Is TQ Therapeutics a private or public company?
TQ Therapeutics is a Private company.
-
What is TQ Therapeutics’s current revenue?
The current revenue for TQ Therapeutics is .
-
Who are TQ Therapeutics’s investors?
Bristol-Myers Squibb, High-Tech Gründerfonds, Juno Therapeutics, and Ventura BioMed Investors have invested in TQ Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
